The neuroprotective effects of --- against embolic stroke in rats by unknown
Hsu et al. Chin Med  (2017) 12:7 
DOI 10.1186/s13020-017-0128-y
RESEARCH
The neuroprotective effects 
of Tao-Ren-Cheng-Qi Tang against embolic 
stroke in rats
Ling‑Wei Hsu1†, Wei‑Cheng Shiao1,2†, Nen‑Chung Chang3, Meng‑Che Yu1, Ting‑Lin Yen1, 
Philip Aloysius Thomas4, Thanasekaran Jayakumar1* and Joen‑Rong Sheu1,5*
Abstract 
Background: Combinations of the traditional Chinese and Western medicines have been used to treat numerous 
diseases throughout the world, and there is a growing body of evidence showing that some of the herbs used in 
traditional Chinese medicine elicit significant pharmacological effects. The aim of this study was to demonstrate the 
neuroprotective effects of Tao‑Ren‑Cheng‑Qi Tang (TRCQT) in combination with aspirin following middle cerebral 
artery occlusion (MCAO)—induced embolic stroke in rats.
Methods: A blood clot was embolized into the middle cerebral artery of rats to induce focal ischemic brain injury. 
After 24 h of MCAO occlusion, the rats were arbitrarily separated into five groups and subjected to different oral treat‑
ment processes with TRCQT and aspirin for 30 days before being evaluated in terms of their neurological behavior 
using a four‑point system. The rats were sacrificed at 30 days after drug treatment and the infarct volumes were meas‑
ured using a 2,3,5‑triphenyltetrazolium chloride staining method. Tumor necrosis factor‑α (TNF‑α), c‑Jun N‑terminal 
kinases (JNK), activated caspase‑3 and Bax were detected by western blot analysis. The apoptotic cells were identified 
by Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. ROS generation was also measured 
by electron spin resonance spectrometry.
Results: Rats treated with TRCQT alone or in combination with aspirin showed a significantly reduced infarct volume 
(P < 0.001) and improved neurological outcome compared with those treated with distilled water. Rats treated with 
TRCQT alone (P = 0.021) or in combination with aspirin (P = 0.02) also showed significantly reduced MCAO‑induced 
expression levels of TNF‑α and pJNK (P < 0.001) in their ischemic regions. Rats treated with TRCQT alone or in combi‑
nation with aspirin showed decreased apoptosis by a reduction in the number of TUNEL positive cells, which inhib‑
ited the expression of activated caspase‑3 (P = 0.038) and Bax (P = 0.004; P = 0.003). TRCQT also led to a significant 
concentration‑dependent reduction in the formation of hydroxyl radicals (P < 0.001).
Conclusions: TRCQT reduced brain infarct volume and improved neurological outcomes by reducing apoptosis, 
attenuating the expression of TNF‑α and p‑JNK, and reducing the formation of hydroxyl radicals in MCAO‑induced 
embolic stroke of rats.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The incidence of stroke has markedly increased in devel-
oping countries over the past four decades [1]. Most 
strokes are caused by a thromboembolism, which dis-
rupts cerebral blood flow, leading to oxygen and glucose 
deprivation in cells [2]. Secondary strokes who the indi-
viduals have a stroke history often have a higher rate of 
death and disability because of existing damage to the 
parts of the brain injured by the original stroke. Aspirin 
has been used to prevent secondary stroke. The inci-
dence of cerebral hemorrhage and other bleeding events 
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is higher in China than it is in people from other high-
income countries [3]. Ischemic brain tissue can be par-
tially prevented from sprouting into infarction by several 
neuroprotective drugs [4]. It is noteworthy however, that 
numerous experimentally effective neuroprotective drugs 
have failed in clinical trials in human because of serious 
side effects [5].
Chinese medicines (CMs) usually contain a large num-
ber of compounds, which can affect multiple targets [6, 
7], and several CMs have been used to treat stroke [8]. 
Previous studies have reported that the well-known Chi-
nese formula Tao-Hong-Si-Wu Tang can be used to treat 
type 2 diabetes [9], as well as several mental disorders, 
including periodic psychosis, mania, neurosis, menopau-
sal syndrome and involutional depression [10]. However, 
Tao-Ren-Cheng-Qi Tang (TRCQT) has not been clini-
cally or experimentally used to treat stroke. In this study, 
we have used TRCQT, which consists of Tao Ren (Pru-
nus persica (L.) Batsch., 5.0 g), Gui Zhi (Cinnamon Twig., 
5.0  g), Mang Xiao (Natrii Sulfas, 5.0  g), Zhi Gan Cao 
(Radix Glycyrrhizae Preparata., 5.0  g) and Da Huang 
(Radix et Rhizoma Rhei.,10  g), to treat ischemic stroke 
in a rat animal model. The aim of this study was to dem-
onstrate the neuroprotective effects of TRCQT in com-
bination with aspirin following a middle cerebral artery 
occlusion (MCAO)-induced embolic stroke in rats.
Methods
Tao‑Ren‑Cheng‑Qi Tang
A dried powder sample of TRCQT (Batch Number, 
161342) was purchased from the Sun Ten Pharma. Co. 
(Taichung, Taiwan). The composition of a 30-g portion of 
this material was as follows: Tao Ren 5.0 g, Gui Zhi 5.0 g, 
Mang Xiao 5.0  g, Da Huang 10  g, Zhi Gan Cao 5.0  g. 
Thirty grams of this herbal mixture was extracted with 
water, yielding 7.0 g of dry extract (30.0:7.0 = 4.3:1). This 
material was mixed with 5 g of corn starch to give 12 g of 
final product. For sample preparation, the dried extract 
of TRCQT was dissolved in sterilized saline water (0.9% 
NaCl) at a concentration of 0.5 g/kg.
Reagents
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) and propidium iodide (PI) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). 
TNF-α, JNK, Bax and activated caspase-3 antibodies 
were purchased from Cell Signaling Technology (Bev-
erly, MA, USA). The anti-α-tubulin mAb was purchased 
from Neo Markers (Fremont, CA, USA). The Hybond-P 
polyvinylidene difluoride membrane, enhanced chemi-
luminescence (ECL) western blotting detection reagent 
and analysis system, horseradish peroxidase (HRP)-con-
jugated donkey anti-rabbit immunoglobulin G (IgG) and 
sheep anti-mouse IgG were purchased from Amersham 
(Buckinghamshire, UK).
MCAO‑induced ischemia rat model
Healthy male Wistar rats (250–300  g) were used in 
this study. All of the animal studies were conducted in 
accordance with the standards established in the Guide 
for the Care and Use of Laboratory Animals, which was 
published by the Institutional Animal Care and Use 
Committee (IACUC) of Taipei Medical University (Addi-
tional file  1). The animal studies were also performed 
in accordance with the ARRIVE guideline (Additional 
file 2). Thirty rats were acclimated for 20 days before dos-
ing, but only 25 of these animals were used the following 
experiments. All of the rats were kept at 37 °C in groups 
of five under a 12-h dark/light cycle with ad  libitum 
access to food and water before the surgery. The rats were 
subjected to MCAO-induced ischemia by the administra-
tion of an autologous blood clot, as described in our pre-
vious studies [11, 12]. After surgery, the rats were housed 
individually under similar environmental conditions and 
were found to be free of apparent infection or inflamma-
tion, as well as showing no neurological deficits. In this 
study, at 24 h after MCA occlusion, the rats were arbitrar-
ily separated into five groups of five rats each, including 
(group 1) sham-operated; (group 2) orally treated with 
distilled water for 30 days, followed by thromboembolic 
occlusion; (groups 3 and 4) treated with aspirin (5  mg/
kg) and TRCQT (0.5 g/kg) alone for 30 days, followed by 
thromboembolic occlusion; and (group 5) treated with 
TRCQT (0.5 g/kg) combined with aspirin (5 mg/kg), fol-
lowed by thromboembolic occlusion.
Neurological functional tests
To assess the neurobehavioral scoring of the animals, a 
sensorimotor integrity was measured for 30  days after 
MCAO by an investigator with no prior knowledge of the 
group allocation (Additional file  3) [13]. The neurologic 
scores were measured by using a 4-point sliding scale. 
Each rat was examined for resistance to lateral push 
(score = 4), open field circling (score = 3) and shoulder 
adduction (score  =  2) or contralateral forelimb flexion 
(score  =  1) when held by the tail. Rats extending both 
forelimbs towards the floor and not showing any other 
signs of neurologic impairment were scored 0. In this 
study, all of the rats subjected to MCAO either exhibited 
a neurologic score of 4 when they were examined 24  h 
after ischemia or immediately before reperfusion, or were 
excluded from the study.
Quantification of brain infarct volume
At 24  h after reperfusion, the rats were anesthetized 
and their brains were removed and cut into 2-mm-thick 
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slices. The slices were then immersed in a 2% solution of 
2,3,5-triphenyltetrazolium chloride (TTC) in phosphate-
buffered saline at 37 °C for 30 min and fixed in 4% phos-
phate buffered formalin. The infarct areas of each slice 
were determined using a computerized image analyzer 
(Image-Pro plus). These areas were then summed and 
multiplied by the slice thickness to give the infarct vol-
umes of each slice, which were calculated according to 
the method reported by Hsiao’s group [11]. None of the 
animals died during these experiments.
Western blot analysis
After 30 days of TRCQT treatment followed by thrombo-
embolic occlusion, the rat brain tissues were collected and 
homogenized, followed by sonication in a lysis buffer con-
taining 20 mM Tris–HCl (pH 7.5), 1 mM MgCl2, 125 mM 
NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluo-
ride, 10  μg/mL leupeptin, 10  μg/mL aprotinin, 25  mM 
β-glycerophosphate, 50 mM sodium fluoride and 100 μM 
sodium orthovanadate. The expression levels of TNF-α, 
phospho-JNK, activated caspase-3 and Bax-2 were ana-
lyzed by immunoblotting, as described previously by 
Rodrigo et  al. [14] with minor modifications. A mixture 
of tris-buffered saline and Tween 20 (TBST) buffer con-
taining 0.1% Tween 20 was used to wash the membranes.
Detection of DNA fragmentation by TUNEL assay
The in situ detection of DNA fragmentation in the brain 
tissues of the rats was performed 30 days after TRCQT 
treatment followed by thromboembolic occlusion using 
a TUNEL detection kit (Millipore, Billerica, Massachu-
setts, USA). Briefly, brain tissues were fixed in 4% formal-
dehyde and embedded in paraffin wax. Five micrometer 
sections of the embedded material were then cut and 
washed for 30 min in PBS. The sections were then equili-
brated in water for 30  min at 37  °C, before being incu-
bated in a mixture of Proteinase K (250  µL) enzyme at 
37 °C for 30 min. The proteinase K digestion process was 
stopped by washing the sections with PBS (four 2-min 
wash cycles). The sections were then incubated in termi-
nal deoxynucleotidyl transferase (TdT) buffer [2.5  mM 
Tris–HCl (pH 6.6), 0.2 M potassium cacodylate, 2.5 mM 
CoCl2, 0.25  mg/mL bovine serum albumin (BSA)] for 
10 min, followed by 60 min at 37 °C in a TdT end-labeling 
cocktail. The TdT end-labeling cocktail was removed and 
the reaction was stopped, and the resulting sections were 
washed in PBS. The sections were incubated in Avidin-
FITC in the dark for 30  min at 37  °C and then washed 
in PBS to end the reaction. The sections were then coun-
terstained with PI for 10 min at 37  °C and mounted on 
a cover slip. Only the green-stained cells were counted 
as belonging to the apoptotic phenotype and the density 
of apoptotic cells was detected by immuno-fluorescent 
microscopy (TCS SP5, Leica, Mannheim, Germany) by 
counting the green-stained cells.
Measurements of hydroxyl radical (OH·−) formation 
by electron spin resonance (ESR) spectrometry
ESR experiments were conducted according to the 
method reported by Chou et al. [15] using a Bruker EMX 
ESR spectrometer (Billerica, MA, USA). Briefly, a Fenton 
reaction solution (50 µm FeSO4 + 2 mM H2O2) was pre-
treated with a solvent control (0.1% DMSO) or TRCQT 
(0.3, 0.7 and 1.3 mg/mL) for 10 min. The rate of hydroxyl 
radical-scavenging activity was defined by the following 
equation:
Statistical analysis
The results were expressed as the mean ±  SD and were 
accompanied by the number of observations. The experi-
ments were assessed by analysis of variance (ANOVA), 
version 9.2 (SAS Inc., Cary, NC, USA), using the New-
man–Keuls method. A P value of less than 0.05 was con-
sidered statistically significant. Concentration-dependent 
effects were determined by visual inspection of the results.
Results
Effect of TRCQT, aspirin alone, or in combination on infarct 
volume
The effects of TRCQT and aspirin alone or in combina-
tion on the infarct volumes are shown in Fig. 1A, B. Com-
pared with the group treated with distilled water (group 
2), the animals treated with TRCQT alone showed a sig-
nificant decrease in their infarct volume (P  <  0.001). In 
contrast, the group treated with aspirin alone (group 3) 
did not show any significant effects. A similar effect was 
also found in rats treated with aspirin combined with 
TRCQT (group 5) (P  <  0.001) for 30  days after MCAO 
compared with the sham-operated (group 1).
Neurobehavioral assessment
Neurological deficit was examined at 24  h after reper-
fusion and scored on a 4-point scale according to the 
method described by Bederson’s group [13]. The changes 
observed in the neurological deficit scores of the differ-
ent groups are shown in Fig. 2. Rats treated with aspirin 
(group 3) for 30  days after MCAO exhibited a moder-
ate reduction in their neurobehavioral scores compared 
with the sham-operated group at 24  h after ischemia 
(P =  0.0525). However, rats treated with TRCQT alone 
(group 4) for 30  days showed a significant reduction in 
their neurobehavioral deficit score compared with the 
sham-operated group at 24  h after thromboembolic 
occlusion (P  =  0.0537). Notably, rats treated with a 
Inhibition rate =
1− [signal height (TRCQT)/signal height (control)]
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combination of aspirin and TRCQT showed a better neu-
robehavioral outcome than those treated those treated 
with TRCQT or aspirin alone (P = 0.0119).
TRCQT enhanced aspirin’s inhibitory effect on TNF‑α 
and p‑JNK in the ischemic brain
As shown in Fig. 3a, there was a significant increase in the 
expression levels of TNF-α in the MCAO-induced group, 
whereas the groups treated with aspirin (P =  0.043) or 
TRCQT (P =  0.021) alone showed significant decreases 
in the expression of this protein. Moreover, a significant 
inhibitory effect was observed in the expression of TNF-α 
in the rats treated with aspirin (0.5 g/kg) combined with 
TRCQT (P = 0.02).
The effects of the TRCQT, aspirin and TRCQT/aspi-
rin combination on the levels of p-JNK are shown in 
Fig.  3b. Compared with the MCAO-induced group, the 
rats treated with TRCQT or aspirin alone showed a sig-
nificant decrease in their p-JNK levels (P  <  0.001). The 
rats treated with a combination of aspirin and TRCQT 
also showed a significant decrease in their expression of 
p-JNK compared with those from the individual treat-
ment groups (P < 0.001).
TRCQT inhibited the apoptosis‑related proteins Bax 
and activated caspase‑3 in the ischemic brain tissues
As shown in Fig.  4a, there was a significant increase 
(P =  0.015) in the levels of Bax protein in the MCAO-
induced group compared with the sham group. Although 
the rats treated with aspirin or TRCQT alone showed a 
significant decrease in the expression of Bax (P = 0.018 
and 0.013, respectively), this effect was potentiated when 
these treatments were combined (P = 0.011).
The expression of activated caspase-3 did not change 
in the sham, MCAO-induced or aspirin treated rats 
(Fig.  4b), but there was significant decrease in the 
expression levels of this protein in the rats treated with 
a combination of aspirin and TRCQT (P =  0.048). The 
rats treated with TRCQT alone also showed a consider-
able decrease in their activated caspase-3 expression, 

















a       b     c        d       e
B
Sham MCAO        aspirin     TRCQT TRCQT
(5 mg/kg)   (0.5 g/kg)  + aspirin
A
Fig. 1 Effects of TRCQT with aspirin against thromboembolic stroke 
in rats. The infarct volume was measured after 30 days of treatment 
with TRCQT, aspirin or a combination of TRCQT and aspirin after 
middle cerebral artery occlusion (MCAO). A TTC (2,3,5‑triphenyltetra‑
zolum chloride solution) staining of the brain slices showing the 
infarct areas in the sham (a), thromboembolic occlusion‑induced 
untreated (b), aspirin (5 mg/kg) (c), TRCQT (0.5 g/kg) (d) and combi‑
nation‑treated groups (e). B Histogram showing the quantification of 
the infarct volumes in the sham, thromboembolic occlusion‑induced 
untreated, aspirin, TRCQT and combination‑treated groups. These 
data represent the mean ± SD of three independent experiments. 
###P < 0.001 compared with sham group, ***P < 0.001 compared with 

























Fig. 2 Effects of TRCQT and aspirin on the neurological deficit. The 
panel shows the neurological deficit scores after stroke in the five 
experimental groups: sham, thromboembolic occlusion‑induced 
untreated, aspirin, TRCQT and combination‑treated. These data repre‑
sent the mean ± SD of three independent experiments. ###P < 0.001 
compared with the sham group, *P < 0.05 compared with the throm‑
boembolic occlusion‑induced untreated group (n = 5)
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Effect of combination of TRCQT and aspirin on DNA 
fragmentation
Although no TUNEL-positive cells were identified in 
the sham-operated group (Fig.  5), we did observe a 
considerable increase in the number of TUNEL-pos-
itive cells in the MCAO-induced group. Rats treated 
with a combination of TRCQT and aspirin showed a 
noticeable reduction in the number of TUNEL-positive 
cells, although this effect was not statistically significant.
TRCQT attenuated the in vitro formation of HO· radicals
TRCQT significantly attenuated the Fenton reaction-
induced formation of HO· radicals in a concentration-
dependent manner (0.3, 0.7 and 1.3  mg/mL) (Fig.  6). 
Moreover, TRCQT inhibited the formation of HO· 





























































Sham       MCAO      aspirin    TRCQT TRCQT
(5 mg/kg)  (0.5 g/kg)  + aspirin
a
Sham       MCAO      aspirin    TRCQT TRCQT
(5 mg/kg)  (0.5 g/kg)   + aspirin
Fig. 3 Effects of TRCQT combined with aspirin on the expressions 
of TNF‑α (a) and p‑JNK (b) in cerebral homogenates 30 days after 
thromboembolic stroke in rats. The data represent the mean ± SD of 
three independent experiments. # and ###P < 0.01 compared with the 
sham‑operated group, * and ***P < 0.05 compared with the throm‑
boembolic occlusion‑induced untreated group. Equal loading in each 

















































Sham       MCAO      aspirin    TRCQT TRCQT
(5 mg/kg)  (0.5 g/kg)  + aspirin
b
a
Sham       MCAO      aspirin    TRCQT TRCQT
(5 mg/kg)  (0.5 g/kg)  + aspirin
Activated caspase-3
-tubulinα
Fig. 4 Effects of TRCQT combined with aspirin on the expression 
levels of Bax (a) and activated caspase‑3 (b) in cerebral homogenates 
30 days after thromboembolic stroke in rats. The data represent the 
mean ± SD of three independent experiments. ##Compared with 
the sham‑operated group, **compared with the thromboembolic 
occlusion‑induced untreated group. Equal loading in each lane was 
demonstrated by similar intensities of α‑tubulin (n = 5)
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1.3 mg/mL compared with a concentration of 0.3 mg/mL 
(P < 0.001).
Discussion
This study demonstrated that the oral treatment with 
TRCQT or aspirin suppressed thromboembolic stroke 
in rats and led to an improved neurological outcome by 
reducing the infarct volume. The treatment of rats with 
TRCQT or aspirin alone inhibited the expression of TNF-
α, p-JNK, activated caspase-3 and Bax, as well as reduc-
ing the number of TUNEL positive cells in the ischemic 
brain regions of these animals. Although the treatment 
of the rats with TRCQT or aspirin alone resulted in neu-
roprotective effects, the combination of these two drugs 
was much more effective. Treatment with TRCQT (0.3, 
0.7 and 1.3 mg/mL) led to a significant reduction in the 
formation of HO· radicals.
Vascular inflammation is mediated by pro-inflamma-
tory cytokines, such as TNF-α [16, 17]. The administra-
tion of TNF-α leads to an increase in tissue damage and 
neurological deficits, thereby aggravating ischemic brain 
injury [18]. Anti-TNF neutralizing antibodies [19] and 
the inhibition of soluble TNF-α receptor type 1 [20] have 
been reported to reduce ischemic damage and improve 
functional outcome after stroke [21]. The results of our 
previous study demonstrated that the oral administra-
tion of Tao-Hong-Si-Wu Tang (THSWT) attenuated the 
effects of embolic stroke by inhibiting the expression 
of TNF-α [22]. In this study, the treatment of MCAO-
induced rats with TRCQT or aspirin alone led to a reduc-
tion in the TNF-α levels. Cerebral ischemia results in an 
increase in the levels of mitogen activated protein kinases 
(MAPKs) [23, 24]. Inhibition of the JNK MAPK path-







Fig. 5 Effects of a combination of TRCQT and aspirin on DNA fragmentation after MCAO injury in rats. TUNEL staining images of damaged cortex 
samples collected from each group after TRCQT combined with aspirin administration at high magnification (25 µm). The TUNEL‑positive material 
was localized in the nuclei of the neurons. Numerous TUNEL‑positive cells were identified in the thromboembolic occlusion‑induced untreated 
group compared with the sham group and the group treated with a combination of TRCQT and aspirin
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brain injury by suppressing the production of inflam-
matory cytokines [25, 26]. The phosphorylation of JNK 
can promote stress-induced cell death and regulate the 
downstream signaling events associated with apoptosis 
during ischemic injury [27]. In this study, we observed 
increases in the activation of TNF-α and p-JNK in rats 
with MCAO-induced brain injury. Notably, the treatment 
of these rats with TRCQT or aspirin alone led a signifi-
cant decrease in the activation of these proteins.
Activated caspase-3 occurs following apoptosis in the 
hippocampus after transient cerebral ischemia-mediated 
neuronal death [28, 29]. The levels of activated caspase-3 
and Bax observed at 30 days after ischemia were higher 
than those found in the sham rats. Furthermore, the 
number of TUNEL-positive cells found in the ischemic 
region increased after MCAO ischemia. The oral admin-
istration of TRCQT in combination with aspirin led to 
significant decreases in the expression levels of Bax and 
activated caspase-3, as well as a reduction in the number 
of TUNEL-positive cells.
The production of reactive oxygen species (ROS) is a 
significant factor in the neuropathology of stroke [30]. 
During acute ischemic stroke, ROS can be generated 
through multiple injury mechanisms, including mito-
chondrial inhibition, Ca2+ overload and reperfusion 
injury [31]. H2O2 is the source of HO· radicals, which 
can contribute to neuronal injury after cerebral ischemic 
reperfusion, resulting in neuronal death [32, 33]. The 
hydroxyl radical-scavenging activity of TRCQT was 
directly evaluated using an ESR method, and the results 
revealed that TRCQT scavenged HO· radicals in a con-
centration-dependent manner.
The screening of traditional Chinese medicines to iden-
tify potential neuroprotective agents by evaluating their 
neuroprotective effects using in vivo and in vitro experi-
mental models of stroke is highly desired. A large amount 
of clinical information has been gathered over the years 
pertaining to the use of Chinese medicines treat stroke 
using indigenous herbal materials [34]. The results of this 
study should provide researchers with a better under-
standing of the mechanisms underlying the therapeutic 
value of using a combination of TRCQT and aspirin to 
treat thromboembolic stroke.
Conclusions
TRCQT reduced brain infarct volume and improved 
neurological outcomes by reducing apoptosis, attenuat-
ing the expression of TNF-α and p-JNK, and reducing the 
formation of HO· radicals in MCAO-induced embolic 
stroke of rats.
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